Newly Diagnosed Glioblastoma
22
8
14
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 22 trials
100.0%
+13.4% vs benchmark
9%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (22)
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
Pembrolizumab for Newly Diagnosed Glioblastoma
A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM
Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma